Comparing the current results to its competitors, Replimune Group Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 9.04 %, recorded in the same quarter.
October 19, 2025
In a significant stride towards revolutionizing treatment options for melanoma and hepatocellular carcinoma (HCC), Replimune Group, Inc. (NASDAQ: REPL), a pioneering clinical-stage biotechnology firm dedicated to novel oncolytic immunotherapies, has showcased robust data from its innovative therapies at prominent oncology conferences in recent months. During the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Dr. Caroline Robert presented compelling data from an ad hoc analysis of the IGNYTE phase 2 cohort studies, investigating the combination of RP1 and nivolumab for patients with acral melanoma (Poster 1644P). This groundbreaking analysis shed light on the efficacy and safety p...
August 22, 2024
In a significant development in the realm of cancer treatment, Replimune Group, Inc. has announced that their late-breaking abstract presenting the primary analysis of the IGNYTE clinical trial has been selected for an oral presentation at the prestigious European Society for Medical Oncology (ESMO) Congress 2024. This eagerly awaited event is set to take place from September 13 to 17 in Barcelona, Spain. Key Insights from the IGNYTE Clinical TrialThe IGNYTE clinical trial represents a crucial component of Replimune s ongoing efforts to innovate within the field of oncolytic immunotherapies. These therapies harness the power of oncolytic viruses, which are genetically engineered to selectively infect and kil...
June 6, 2024
Replimune s RP1 and Nivolumab Combination Therapy Shows Encouraging 12-Month Overall Response Rate in Anti-PD1 Failed Melanoma Melanoma remains one of the most challenging cancers to treat, with a significant subset of patients failing to respond to available therapies. However, an encouraging breakthrough has emerged from the IGNYTE clinical trial led by Replimune, showcasing the therapeutic potential of combining RP1, an oncolytic immunotherapy, with Nivolumab, a PD-1 inhibitor. This innovative approach aims to address the unmet needs of patients with anti-PD1 failed melanoma. Primary Analysis Highlights Replimune recently announced positive topline primary analysis data by Independent Central Review fro...
Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.
Prime Medicine Inc is a biotechnology company specializing in gene editing technologies and therapeutics. Their business model revolves around harnessing advanced CRISPR-based gene editing techniques to develop treatments for genetic diseases. By using innovative science and strategic partnerships, the company aims to bring transformative therapies to patients in need.
Sana Biotechnology Inc operates as a biotechnology company that focuses on developing and commercializing cellular therapies for various diseases. Their business model involves leveraging innovative technologies and collaborations with clinical and industry partners to develop advanced medical treatments.
Sangamo Therapeutics Inc is a biotechnology company that focuses on developing genomic medicines. Their business model revolves around utilizing gene-editing technology to create therapies for genetic and rare diseases. They engage in research, development, and commercialization of their proprietary technologies to deliver innovative treatments with the potential to transform patients' lives.
Autolus Therapeutics Plc is a biopharmaceutical company that focuses on the development and commercialization of next-generation engineered T-cell therapies for the treatment of cancer. Their business model is centered around utilizing innovative technology and expertise to create and advance novel therapies aimed at improving patient outcomes in oncology.
Sources:
Replimune Group Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Replimune Group Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
